AstraZeneca will invest $2.5 billion in a new R&D center in Beijing.

AstraZeneca has announced a $2.5 billion investment to establish its sixth global strategic research and development (R&D) center in Beijing. This initiative is part of a broader strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office. The investment, which will unfold over the next five years, also includes agreements with three biotechnology firms: Harbour BioMed, Syneron Bio, and BioKangtai.

Pascal Soriot, CEO of AstraZeneca, stated, "This $2.5 billion investment reflects our confidence in the world-class life sciences ecosystem in Beijing, the vast opportunities for collaboration, access to talent, and our ongoing commitment to China." The new R&D center will focus on early-stage research and clinical development, supported by cutting-edge artificial intelligence and data science laboratories, and will be strategically located near leading biotech firms and research hospitals in the Beijing International Pharmaceutical Innovation Park (BioPark).